Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion.

BACKGROUND AIMS Mesenchymal stromal cells (MSCs) exhibit the inherent potential to regulate multiple signaling pathways and cell types that contribute to the pathogenesis of inflammatory and immune diseases. However, more recent studies have suggested that the secretion of immunomodulatory factors by MSCs can be enhanced by three-dimensional aggregation or pro-inflammatory cytokine treatment. METHODS Human MSC spheroids were formed by forced aggregation into agarose micro-wells and subsequently cultured in either minimal essential medium alpha supplemented with fetal bovine serum or serum-free, defined MesenCult-XF medium (STEMCELL Technologies, Vancouver, Canada). A subset of the spheroids were treated with pro-inflammatory cytokines interferon (IFN)-γ or tumor necrosis factor (TNF)-α or both for 4 days. Immunomodulatory factor (prostaglandin E2, indoleamine 2,3-dioxygenase, transforming growth factor-β1 and interleukin-6) secretion was quantified after 4 days of culture, and the immunomodulatory activity of MSCs was assessed by quantifying activated macrophage expression of TNF-α after trans-well co-culture. RESULTS Culturing human MSCs as three-dimensional aggregates increased secretion of immunomodulatory paracrine factors, which was enhanced further by treatment with IFN-γ and TNF-α, demonstrating that these parameters can synergistically enhance endogenous human MSC immunomodulatory properties. However, immunomodulatory factor secretion was found to be highly dependent on the composition of cell culture medium. Human MSCs cultured in MesenCult-XF medium displayed significantly less expression of prostaglandin E2, indoleamine 2,3-dioxygenase, transforming growth factor-β1 and interleukin-6 compared with human MSCs cultured in medium supplemented with fetal bovine serum. Finally, pre-conditioning of human MSC spheroids with IFN-γ and TNF-α resulted in greater immunomodulatory activity in a macrophage co-culture assay. CONCLUSIONS Altogether, engineering the environment of human MSCs to develop pre-conditioning strategies for enhancing human MSC immunomodulation may be a simple approach for improving MSC-based therapies for the treatment of inflammatory and immune diseases.

[1]  Hao Wang,et al.  Regulatory T-Cell Generation and Kidney Allograft Tolerance Induced by Mesenchymal Stem Cells Associated With Indoleamine 2,3-Dioxygenase Expression , 2010, Transplantation.

[2]  Kazuo Suzuki,et al.  Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.

[3]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[4]  Hulun Li,et al.  Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β , 2009, Journal of Neuroimmunology.

[5]  Haisheng Peng,et al.  TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4+ T cell subsets. , 2008, Cellular immunology.

[6]  W. Weimar,et al.  Effects of Hypoxia on the Immunomodulatory Properties of Adipose Tissue-Derived Mesenchymal Stem cells , 2013, Front. Immunol..

[7]  S. Morbelli,et al.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells , 2011, Proceedings of the National Academy of Sciences.

[8]  M. Selig,et al.  Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes1 , 2009, The Journal of Immunology.

[9]  S. Raiden,et al.  Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profile , 2010, PloS one.

[10]  J. Ryan,et al.  Interferon‐γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells , 2007 .

[11]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[12]  H. Lorenz,et al.  Multilineage cells from human adipose tissue: implications for cell-based therapies. , 2001, Tissue engineering.

[13]  R. Cancedda,et al.  Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. , 2012, Investigative ophthalmology & visual science.

[14]  D. Prockop,et al.  Human Mesenchymal Stem/Stromal Cells Cultured as Spheroids are Self‐activated to Produce Prostaglandin E2 that Directs Stimulated Macrophages into an Anti‐inflammatory Phenotype , 2012, Stem cells.

[15]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[16]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[17]  Gabriel Courties,et al.  IL-6-Dependent PGE2 Secretion by Mesenchymal Stem Cells Inhibits Local Inflammation in Experimental Arthritis , 2010, PloS one.

[18]  Todd C McDevitt,et al.  Systematic analysis of embryonic stem cell differentiation in hydrodynamic environments with controlled embryoid body size. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[19]  Andrea Bacigalupo,et al.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  C. Jorgensen,et al.  Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell Phenotype , 2010, The Journal of Immunology.

[21]  F. Benvenuto,et al.  Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.

[22]  E. J. Lee,et al.  Spherical bullet formation via E-cadherin promotes therapeutic potency of mesenchymal stem cells derived from human umbilical cord blood for myocardial infarction. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Nan Ma,et al.  Bcl‐2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function , 2007, Stem cells.

[24]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[25]  S. Agaugué,et al.  1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity1 , 2006, The Journal of Immunology.

[26]  R. Willemze,et al.  Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells1 , 2006, The Journal of Immunology.

[27]  G. Damonte,et al.  Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.

[28]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[29]  Manuel A. González,et al.  Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. , 2009, Gastroenterology.

[30]  Arnold I Caplan,et al.  Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models , 2012, Nature Neuroscience.

[31]  D. García-Olmo,et al.  A Phase I Clinical Trial of the Treatment of Crohn’s Fistula by Adipose Mesenchymal Stem Cell Transplantation , 2005, Diseases of the colon and rectum.

[32]  Todd C McDevitt,et al.  Stem cell paracrine actions and tissue regeneration. , 2010, Regenerative medicine.

[33]  Min-jung Park,et al.  Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10 , 2009, Experimental & Molecular Medicine.

[34]  D. Prockop,et al.  Dynamic compaction of human mesenchymal stem/precursor cells into spheres self‐activates caspase‐dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1) , 2013, Stem cells.

[35]  M. Toungouz,et al.  Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. , 2010, Cellular immunology.

[36]  Jakub Tolar,et al.  Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells , 2010, Stem cells.

[37]  L. Moretta,et al.  Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. , 2008, Blood.

[38]  S. Haynesworth,et al.  Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation , 2004, Bone Marrow Transplantation.

[39]  Nikolay Bazhanov,et al.  Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties , 2010, Proceedings of the National Academy of Sciences.

[40]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[41]  D. Munn,et al.  Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells1 , 2004, The Journal of Immunology.

[42]  N. Câmara,et al.  Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? , 2011, World journal of stem cells.

[43]  G. Shaw,et al.  Mesenchymal stem cell inhibition of T‐helper 17 cell‐ differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor , 2011, European journal of immunology.

[44]  M. Baccarani,et al.  Tolerance: Focus on Hematology the Role of Indoleamine 2,3-dioxygenase in the Induction of Immune , 2008 .

[45]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.

[46]  Ruth S. Waterman,et al.  A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype , 2010, PloS one.

[47]  P. Conget,et al.  Mesenchymal progenitor cells in human umbilical cord blood , 2000, British journal of haematology.

[48]  C. V. van Blitterswijk,et al.  Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. , 2012, Tissue engineering. Part B, Reviews.

[49]  Karim Oudina,et al.  Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. , 2007, Bone.

[50]  K. English.  Mechanisms of mesenchymal stromal cell immunomodulation , 2013, Immunology and cell biology.

[51]  J. Ingwall,et al.  Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  L. Rosenberg,et al.  Ex Vivo Expansion of Human Mesenchymal Stem Cells in Defined Serum-Free Media , 2012, Stem cells international.

[53]  L. Moretta,et al.  Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T‐ and NK‐cell proliferation and function , 2011, European journal of immunology.

[54]  Michael S. Kallos,et al.  Effects of Hydrodynamics on Cultures of Mammalian Neural Stem Cell Aggregates in Suspension Bioreactors , 2001 .

[55]  T. Yi,et al.  Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications , 2012, Archives of Pharmacal Research.

[56]  F. Djouad,et al.  Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin‐6‐Dependent Mechanism , 2007, Stem cells.

[57]  P. Zandstra,et al.  Reproducible, Ultra High-Throughput Formation of Multicellular Organization from Single Cell Suspension-Derived Human Embryonic Stem Cell Aggregates , 2008, PloS one.

[58]  Seung-Woo Cho,et al.  Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells. , 2011, Biomaterials.

[59]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[60]  F. Barry,et al.  IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells , 2007 .

[61]  Lingyun Sun,et al.  Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans , 2009, Stem cells.

[62]  I. Sekiya,et al.  Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality , 2002, Stem cells.

[63]  Jacques Galipeau,et al.  Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  D. Strunk,et al.  Immunomodulative Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells Cultured in Human Platelet Lysate , 2011, Journal of Clinical Immunology.

[65]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[66]  F. Uher,et al.  Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. , 2012, Biochemical and biophysical research communications.

[67]  Shilpa Shankar,et al.  Pro-Inflammatory Cytokines, IFNγ and TNFα, Influence Immune Properties of Human Bone Marrow and Wharton Jelly Mesenchymal Stem Cells Differentially , 2010, PloS one.

[68]  N. Palaniyar,et al.  NET balancing: a problem in inflammatory lung diseases , 2013, Front. Immun..

[69]  M. Weller,et al.  Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R , 2009, Stem cells.